

**UNITED STATES DISTRICT COURT  
DISTRICT OF MASSACHUSETTS**

Astellas Institute for Regenerative Medicine, and  
Stem Cell & Regenerative Medicine International,  
Inc.,

Plaintiffs,

v.

ImStem Biotechnology, Inc.,  
Xiaofang Wang, and  
Ren-He Xu,

Defendants.

C.A. No. 1:17-cv-12239

**CORPORATE DISCLOSURE STATEMENT FOR**  
**ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE**

Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, and to enable Judges and Magistrate Judges of the Court to evaluate possible disqualification or recusal, the undersigned counsel for Plaintiff Astellas Institute for Regenerative Medicine (“Astellas”) respectfully submits the following corporate disclosure statement.

Astellas Institute for Regenerative Medicine is a wholly owned, indirect subsidiary of Astellas Pharma, Inc. Astellas Pharma Inc. is publicly traded on the Tokyo stock exchange. Astellas Pharma Inc. has no parent corporation, and no publicly-held corporation holds 10% or more of its stock.

Respectfully Submitted,

Dated: November 13, 2017

/s/ Charles H. Sanders

---

Charles H. Sanders  
Massachusetts Bar # 646740  
LATHAM & WATKINS LLP  
200 Clarendon St.  
Boston, MA 02116  
(617) 948-6000  
charles.sanders@lw.com

*Attorneys for Plaintiff  
Astellas Institute for Regenerative Medicine*

Of Counsel:

Michael A. Morin  
michael.morin@lw.com  
David P. Frazier  
david.frazier@lw.com  
Rebecca L. Rabenstein  
rebecca.rabenstein@lw.com  
Abigail A. Rives  
abigail.rives@lw.com  
LATHAM & WATKINS LLP  
555 Eleventh St., NW  
Suite 1000  
Washington, D.C. 20004  
(202)637-2200

Lauren K. Sharkey  
lauren.sharkey@lw.com  
LATHAM & WATKINS LLP  
330 North Wabash Avenue  
Suite 2800  
Chicago, IL 60611  
(312) 876-7700